|Slideshows|December 13, 2018

5 Classic Hallucinogens Studied in the Treatment of Addictions

This slideshow provides information about the compounds, clinically relevant attributes, approximate dose, and data under study.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Digital Apps for Substance Use Reduction: Discussion With InvestigatorJon-Patrick Allem, PhD

ByJon-Patrick Allem, PhD

November 27th 2025

Breaking the Cycle: Jail Diversion as an Alternative to Incarceration for Individuals With Co-Occurring Disorders

ByMichèle Haykal, MD,Nidal Moukaddam, MD, PhD

November 19th 2025

Identifying and Treating High Functioning Substance Use Disorder

ByRachel Rohaidy, MD

November 10th 2025

TMS ketamine depression substance use disorder

Combination Therapy With TMS and Ketamine for Depression, Neuropathic Pain, and Substance Use Disorder: A Network-Based Approach

BySteven R. Devore Best, MD

November 5th 2025

Positive FDA Meeting for Abuse Deterrent Fentanyl Patch

ByJessica Walters

October 29th 2025

Latest CME

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

5 Classic Hallucinogens Studied in the Treatment of Addictions

Newsletter

Related Content

Digital Apps for Substance Use Reduction: Discussion With InvestigatorJon-Patrick Allem, PhD

Breaking the Cycle: Jail Diversion as an Alternative to Incarceration for Individuals With Co-Occurring Disorders

Identifying and Treating High Functioning Substance Use Disorder

Combination Therapy With TMS and Ketamine for Depression, Neuropathic Pain, and Substance Use Disorder: A Network-Based Approach

Positive FDA Meeting for Abuse Deterrent Fentanyl Patch

Latest CME

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

November in Review: Updates on the Psychiatric Treatment Pipeline

Looking Back: Key Insights from November 2025

Lithium Reduces Risk of Suicide and Recurrent Episodes of Bipolar and Major Depressive Disorders

The Truth About Insomnia and Melatonin: Natural Does Not Always Mean Harmless

The Hybrid Model: Humans & Chatbots Working Together